Selective targeting of metastatic ovarian cancer using an engineered anthrax prodrug activated by membrane-anchored serine proteases

Treatments for advanced and recurrent ovarian cancer remain a challenge due to a lack of potent, selective, and effective therapeutics. Here, we developed the basis for a transformative anticancer strategy based on anthrax toxin that has been engineered to be selectively activated by the catalytic p...

Descripción completa

Detalles Bibliográficos
Autores principales: Duru, Nadire, Pawar, Nisha R., Martin, Erik W., Buzza, Marguerite S., Conway, Gregory D., Lapidus, Rena G., Liu, Shihui, Reader, Jocelyn, Rao, Gautam G., Roque, Dana M., Leppla, Stephen H., Antalis, Toni M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: National Academy of Sciences 2022
Materias:
Biological Sciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9282395/
https://www.ncbi.nlm.nih.gov/pubmed/35867758
http://dx.doi.org/10.1073/pnas.2201423119

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9282395/
https://www.ncbi.nlm.nih.gov/pubmed/35867758
http://dx.doi.org/10.1073/pnas.2201423119

Ejemplares similares